Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De Sells 7,373 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 7,373 shares of the company’s stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $9.14, for a total value of $67,389.22. Following the transaction, the executive vice president now directly owns 79,460 shares in the company, valued at $726,264.40. This represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Verneuil Vanina De also recently made the following trade(s):

• On Monday, December 2nd, Verneuil Vanina De sold 76 shares of Vir Biotechnology stock. The shares were sold at an average price of $8.22, for a total value of $624.72.

Vir Biotechnology Stock Up 3.5 %

Shares of VIR opened at $8.39 on Friday. Vir Biotechnology, Inc. has a 52 week low of $6.56 and a 52 week high of $14.45. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -2.14 and a beta of 0.64. The stock’s 50-day moving average price is $9.46 and its 200-day moving average price is $8.49.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.09. The company had revenue of $12.37 million during the quarter, compared to analysts’ expectations of $8.14 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. As a group, equities analysts anticipate that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Vir Biotechnology

Large investors have recently bought and sold shares of the business. State of Alaska Department of Revenue raised its holdings in Vir Biotechnology by 33.0% in the 4th quarter. State of Alaska Department of Revenue now owns 202,441 shares of the company’s stock worth $1,485,000 after purchasing an additional 50,199 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Vir Biotechnology by 13.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company’s stock valued at $8,496,000 after acquiring an additional 136,087 shares during the last quarter. State Street Corp raised its holdings in shares of Vir Biotechnology by 10.4% during the third quarter. State Street Corp now owns 5,625,533 shares of the company’s stock valued at $42,135,000 after acquiring an additional 530,645 shares during the last quarter. abrdn plc acquired a new position in shares of Vir Biotechnology during the fourth quarter valued at approximately $2,666,000. Finally, Intech Investment Management LLC acquired a new position in shares of Vir Biotechnology during the third quarter valued at approximately $191,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

Analysts Set New Price Targets

VIR has been the topic of several research analyst reports. Barclays boosted their price target on Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a research note on Friday. Morgan Stanley upgraded Vir Biotechnology from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. JPMorgan Chase & Co. boosted their price target on Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research note on Thursday, January 9th. HC Wainwright reiterated a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a research note on Friday. Finally, Needham & Company LLC restated a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $35.67.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).